Lorlatinib
Brand Names: Lorbrena
Methodology & AI Transparency ⓘ
Lorlatinib Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage lorbrena: ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
- 2 Real-world patient consensus: Tracked across 14 patient dosage logs with a 90% satisfaction benchmark (RxCUI 2103169).
- 3 Typical cash cost range: Public pharmacy ledger: $26.32 low cash benchmark vs. $64.48 chain retail average ($0.4400/unit CMS NADAC).
- 4 Top reported side effects / signs: Most commonly reported Lorlatinib tolerability events: diarrhea (9.7%), fatigue (6.5%), arthralgia (5%).
Ask our AI Specialists anything about Lorlatinib
Lorlatinib Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage lorbrena: ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )
12.1 Mechanism of Action Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors.
With Terminal t½ estimated at 10–16 hrs depending on renal/hepatic reserve (Lorlatinib) residence kinetics and F ≈ 61%–73% systemic availability after standard oral Lorlatinib administration bioavailability, Lorlatinib undergoes mixed metabolic conjugation and unchanged urinary excretion across lorlatinib regimens and establishes therapeutic activity over time to peak concentration spans 1 to 3 hrs under lorlatinib maintenance.
Standard adult regimens span 100 mg/1 Tablet, Film Coated, 25 mg/1 Tablet, Film Coated. Prescribers screen specifically against 4 contraindications lorbrena is contraindicated in patients taking strong cyp3a inducers, due to the potential for serious hepatotoxicity .; concomitant use with strong cyp3a inducers., while community micro-logs most frequently note diarrhea (9.7% of reports), nausea (9% of reports), fatigue (6.5% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Lorlatinib (kinase inhibitor).
Botanical enzyme modulators may alter oral first-pass exposure of Lorlatinib; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity .
- Concomitant use with strong CYP3A inducers.
Logged Side-Effect Incidence (14 Reports)
Lorlatinib Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lorlatinib)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Kinetics and management of side effects associated with lorlatinib after 5 years After 5 years of follow-up, no new safety signals were observed. The oncologist • 2025-10-01 • Phase III Randomized Trial | N = 149 | 82/100 | PMID 41124598 ↗ |
Lorlatinib Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4400/unit (~$13.20/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $64.48 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $26.32 / mo | View logs ↓ |
Lorlatinib Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Lorlatinib RxNorm Concept ID | 2103169 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $64.48 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $26.32 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Lorlatinib Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Lorlatinib integrating DailyMed SPL (2026-06-26), CMS NADAC ($0.4400/unit), and 14 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Lorlatinib community threads and patient logs by age, biological sex, dosage, and treatment duration.